European Committee for Homeopathy

MEETING AGENDA

COUNCIL

Meeting name/purpose	Council meeting		
Date	25.3.2020	**Time**	17.30 CET
Location	Zoom		
Attendees	Hélène Renoux, Sara Eames, Ilse Muchitsch, Jean Pierre Jansen, Dora Pachova, Tiziana di Giampietro, Hetty Buitelaar, Jaume Costa	**Apologies**	Cristal Sumner, Margaret Wyllie, Arlette Blanchy
Minutes to be written by	Jaume Costa	**Moderator**	Sara Eames
Distribution	Council members	**Enclosures**	*Minutes previous Council meeting*

AGENDA

Item	Time 14/11/19	Agenda topic	Presenter
1	17:30 – 17:35	*Welcome and approval of agenda. Minutes previous Council are already approved.*	Sara Eames
2	17.35 – 18.00	*Case collection projects (Lex Rutten, Robbert Van Haselen), IT support (Clificol, Vithoulkas Compass), LMHI coordination, Scientific committee, national contact points*	Hélène Renoux Tiziana di Giampietro
3	18:00 – 18:10	*Covid19 page in ECH restricted website section*	Sara Eames Jaume Costa
4	18:10 – 18:20	*Homeoprophylaxis (LMHI, Finley Institute in Cuba)*	Jaume Costa
5	18:20 – 18:30	*AOB*	ALL

European Committee for Homeopathy

MEETING AGENDA

DISCUSSION OF TOPICS

1	*17:30 – 17:35*	*Welcome and approval of agenda and previous meeting minutes*	Sara Eames
Conclusion		Sara welcomed the participants. The minutes of the previous Council had already been approved. No AOB to be discussed.	

2	*17.35 – 18.10*	*Case collection projects (Lex Rutten, Robbert Van Haselen), IT support (Clificol, Vithoulkas Compass), LMHI coordination, Scientific committee, national contact points*	Hélène Renoux Tiziana di Giampietro
		Hélène informed of the email from Yvonne Fok on the Clificol/Corona project. Hélène had concerns about ownership, use of the data and goals of the case collection, being out of control of the European prescribers.	
Jean Pierre summarised that the case collection could be done through Clificol and Vithoulkas Compass. He highlighted the importance to differentiate between tested and non-tested cases and that the tests should be validated. Possible tests to be used are the PCR for detecting the virus and the serology, antibodies test (IgG, IgM). Jean Pierre underlined that there should be patients' consent and doctors' agreement. Hélène added that scientific advisers coming from European scientific societies should be involved in the process to ensure the full cooperation with national ongoing projects.			
Dora suggested that each country should have access to its own data.			
This is also an LMHI project and there are groups in China and USA involved.			
Jean Pierre suggested that the projects become open access. This will incentive doctors to submit data and it will allow data analysis by everyone. The data will be interesting for other researchers with other research questions. Access from bona fide researchers is useful for ECH and should be regulated. Publications should go to peer reviewed journals and made available to the public using the open access mechanism that many journals have.			
Jaume proposed that ECH endorses both projects but does not take full responsibility for the projects.			
Jean Pierre will draft a document on the data ownership that will be submitted to Frederik Schroyens for discussion. Then it will be submitted to the Council for approval.			
Sara underlined the importance of differentiating between tested and non-tested cases.			
Ilse brought to the attention of the Council that remedies that are not included in the Pharmacopoeias should not be part of the research. The proposal from Clificol should take this into account. She warned that doing otherwise means being open to criticism from the sceptics. Jean Pierre clarified that the remedies to be part of the project are the ones			

Conclusion	The Council wants that the ownership and access to the data is clarified.		
Action items		**Person responsible**	**Deadline**
Draft on ownership of the data and discussion with Frederik Schroyens		Jean Pierre	27/03/2020
Approval of the draft on data ownership and access		ALL	30/03/2020
3	*18:10 – 18:20*	*Covid19 page in ECH restricted website section*	Sara Eames Jaume Costa
	Sara explained that the UK Faculty has set up a new webpage on Covid19 in their members' only website section. Hetty referred to a Dutch IT platform that allows sharing cases between practitioners.		
Jaume suggested that a similar ECH webpage could include different articles on Covid19 and a disclaimer that the ECH is not endorsing any of the papers.			
Hélène was concerned about the quality of the papers. Hetty considered that only members of the subcommittees should have access to the webpage.			
Sara mentioned that two papers published by Homeopathy are on the UK webpage and could be shared with ECH. Jean Pierre referred to the Paolo Bellavite article on homeopathy and influenza. Dora referred to an article about the bird flu by Michael Van Wassenhoven and the Russell Malcolm's seminar on Covid19.			
Conclusion	It was decided to include only peer reviewed journals, articles in the public domain and the disclaimer. The access should be restricted to subcommittees' members only.		
Action items		**Person responsible**	**Deadline**
Ask Martin to set up the webpage		Jaume	15/04/2020
Update papers to the webpage		ALL	ongoing

4	*18:20 – 18:30*	*Homeoprophylaxis (LMHI, Finley Institute in Cuba)*	Jaume Costa
	Sara and Hélène considered that homeoprophylaxis is not an appropriate topic for ECH. On the other hand, countries outside Europe may consider homeoprophylaxis. It would be up to the LMHI to take action.		
Dora informed that there are nosodes produced by Ainsworth and in Germany also. Ilse stated her concern about mentioning any Covid -19 nosode, when the homeopathic industry is not yet producing an EU accepted homeopathic medicine.			
Jean Pierre has requested a certificate of sterilization from Ainsworth. Ilse underlined that having a certificate of sterilization is not enough. Ilse highlighted that the European Pharmacopoeia and the applicable Directives need to be considered. She spelled out that a macroscopic and microscopic description of the raw material should be provided. In addition, the donor (human/animal) needs to be identified and coded for traceability in accordance with Article 8 (1) of the Directive 2004/23/EC. Moreover, the raw material should comply with current European Pharmacopoeia Monographs			

(0853-Human plasma for fractionation, 1483- Products with risk of transmitting agents of animal spongiform encephalopathies) and the requirements on tissue(s) of the Directive 2004/23/EC. Human material may contain blood or may have been exposed to it during the extraction process, so the transmission of viruses is of particular concern, therefore the selection of the donors must comply with the Commission Directive 2004/33/EC, implementing Directive 2002/98/EC of the European Parliament and of the Council.	
Conclusion	No action to be taken.